Wild-type transthyretin amyloid

Wild-type transthyretin amyloid accumulates mainly in the heart, where it causes stiffness and often thickening of its walls, leading consequently to shortness of breath and intolerance to exercise, called diastolic dysfunction. Excessively slow heart rate can also occur, such as in sick sinus syndrome, with ensuing fatigue and dizziness. Wild-type transthyretin deposition is also a common cause of carpal tunnel syndrome in elderly men, which may cause pain, tingling and loss of sensation in the hands. Some patients may develop carpal tunnel syndrome as an initial symptom of wild-type transthyretin amyloid.{{cite journal | vauthors = Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T, Hoshii Y, Kato H, Ikeda S | title = High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly | journal = Human Pathology | volume = 42 | issue = 11 | pages = 1785–91 | date = November 2011 | pmid = 21733562 | doi = 10.1016/j.humpath.2011.03.004 | url = https://soar-ir.repo.nii.ac.jp/?action=repository_uri&item_id=8066 | type = Submitted manuscript | hdl = 10091/16883 | hdl-access = free }}

There appears to be an increased risk of developing hematuria or blood in the urine due to urological lesions.{{cn|date=November 2024}}

The disorder typically affects the heart and its prevalence increases in older age groups. Men are affected much more frequently than women,{{cite journal |vauthors=Ng B, Connors LH, Davidoff R, Skinner M, Falk RH |date=June 2005 |title=Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis |journal=Archives of Internal Medicine |volume=165 |issue=12 |pages=1425–9 |doi=10.1001/archinte.165.12.1425 |pmid=15983293 |doi-access=free}} and up to 25% of men over the age of 80 may have evidence of WTTA.{{cite journal | vauthors = Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L | title = Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study | journal = Annals of Medicine | volume = 40 | issue = 3 | pages = 232–9 | date = 2008-01-01 | pmid = 18382889 | doi = 10.1080/07853890701842988 | s2cid = 23446885 }}

Patients often present with increased thickness of the wall of the main heart chamber, the left ventricle. People affected by WTT amyloidosis are likely to have required a pacemaker before diagnosis and have a high incidence of a partial electrical blockage of the heart, known as the left bundle branch block. Low ECG signals such as QRS complexes are widely considered a marker of cardiac amyloidosis.{{cite journal | vauthors = Falk RH | title = Diagnosis and management of the cardiac amyloidoses | journal = Circulation | volume = 112 | issue = 13 | pages = 2047–60 | date = September 2005 | pmid = 16186440 | doi = 10.1161/CIRCULATIONAHA.104.489187 | doi-access = free }}

A much better survival has been reported for patients with WTTA as opposed to cardiac AL amyloidosis.{{cite journal | vauthors = Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S | title = Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types | journal = Circulation | volume = 120 | issue = 13 | pages = 1203–12 | date = September 2009 | pmid = 19752327 | doi = 10.1161/CIRCULATIONAHA.108.843334 | doi-access = free }}

The condition is suspected in an elderly person, especially male, presenting with symptoms of heart failure such as shortness of breath or swollen legs, and or disease of the electrical system of the heart with ensuing slow heart rate, dizziness or fainting spells.{{cite journal | vauthors = Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD | title = Updates in cardiac amyloidosis: a review | journal = Journal of the American Heart Association | volume = 1 | issue = 2 | pages = e000364 | date = April 2012 | pmid = 23130126 | doi = 10.1161/JAHA.111.000364 | pmc = 3487372 }} The diagnosis is confirmed on the basis of a biopsy, which can be treated with a special stain called Congo Red that will be positive in this condition, and immunohistochemistry. However, this disease can now non-invasively be diagnosed with the help of Tc-99m pyrophosphate scintigraphy.{{cite journal | last1=Masri | first1=Ahmad | last2=Bukhari | first2=Syed | last3=Ahmad | first3=Shahzad | last4=Nieves | first4=Ricardo | last5=Eisele | first5=Yvonne S. | last6=Follansbee | first6=William | last7=Brownell | first7=Amy | last8=Wong | first8=Timothy C. | last9=Schelbert | first9=Erik | last10=Soman | first10=Prem | title=Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis | journal=Circulation: Cardiovascular Imaging |volume=13 | issue=2 | year=2020 | issn=1941-9651 | doi=10.1161/circimaging.119.010249|doi-access=free| page=e010249| pmid=32063053 | pmc=7032611 }}

No drug has been shown to be able to arrest or slow down the process of this condition.{{cite journal | vauthors = Dubrey S, Ackermann E, Gillmore J | title = The transthyretin amyloidoses: advances in therapy | journal = Postgraduate Medical Journal | volume = 91 | issue = 1078 | pages = 439–48 | date = August 2015 | pmid = 26048914 | doi = 10.1136/postgradmedj-2014-133224 | s2cid = 8077907 }} There is promise that two drugs, tafamidis and diflunisal,{{cite journal | vauthors = Sekijima Y | title = Recent progress in the understanding and treatment of transthyretin amyloidosis | journal = Journal of Clinical Pharmacy and Therapeutics | volume = 39 | issue = 3 | pages = 225–33 | date = June 2014 | pmid = 24749898 | doi = 10.1111/jcpt.12145 | s2cid = 20492854 | doi-access = free }} may improve the outlook, since they were demonstrated in randomized clinical trials to benefit patient affected by the related condition FAP-1 otherwise known as transthyretin-related hereditary amyloidosis. Permanent pacing can be employed in cases of symptomatic slow heart rate (bradycardia). Heart failure medications can be used to treat symptoms of difficulty breathing and congestion.{{cite journal | vauthors = Quarta CC, Kruger JL, Falk RH | title = Cardiac amyloidosis | journal = Circulation | volume = 126 | issue = 12 | pages = e178–82 | date = September 2012 | pmid = 22988049 | doi = 10.1161/CIRCULATIONAHA.111.069195 | doi-access = free }}

A 2021 investigational first-in-human study demonstrated that NTLA-2001, a therapeutic agent based on the CRISPR-Cas9 system, induces targeted knockout of the transthyretin protein.{{Cite journal|last1=Gillmore|first1=Julian D.|last2=Gane|first2=Ed|last3=Taubel|first3=Jorg|last4=Kao|first4=Justin|last5=Fontana|first5=Marianna|last6=Maitland|first6=Michael L.|last7=Seitzer|first7=Jessica|last8=O'Connell|first8=Daniel|last9=Walsh|first9=Kathryn R.|last10=Wood|first10=Kristy|last11=Phillips|first11=Jonathan|date=2021-08-05|title=CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis|journal=New England Journal of Medicine|language=en|volume=385|issue=6|pages=493–502|doi=10.1056/NEJMoa2107454|pmid=34215024 |s2cid=235722446 |issn=0028-4793|doi-access=free}}

Because of preliminary data suggesting the drug may have activity, the U.S. FDA in 2013 granted tolcapone "orphan drug status" in studies aiming at the treatment of transthyretin familial amyloidosis (ATTR).{{cite web | title=Tolcapone| website=FDA: Search Orphan Drug Designations and Approvals| date=1 January 2013 | url=https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=413913| archive-url=https://web.archive.org/web/20210726041630/https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=413913| url-status=dead| archive-date=July 26, 2021}} However, {{As of|2015|lc=y}} tolcapone was not FDA approved for the treatment of this disease.{{cite journal| pmc=4642128 | page=P9 | volume=10 | issue=Suppl 1 | journal=Orphanet J Rare Dis | title=SOM0226, a repositioned compound for the treatment of TTR amyloidosis | year=2015 | doi=10.1186/1750-1172-10-s1-p9| last1=Reig | first1=N. | last2=Ventura | first2=S. | last3=Salvadó | first3=M. | last4=Gámez | first4=J. | last5=Insa | first5=R. | doi-access=free }}

• Transthyretin-related hereditary amyloidosis
• Amyloidosis

{{reflist|32em}}

• [http://www.bu.edu/amyloid/ The Amyloidosis Center at Boston University]
• [http://www.mayoclinic.org/diseases-conditions/amyloidosis/basics/definition/con-20024354 Mayo Clinic Definition]
• [http://www.brighamandwomens.org/Departments_and_Services/medicine/services/cvcenter/Amyloidosis/patients.aspx A Patient Guide to Amyloidosis]

Category:Amyloidosis

Category:Histopathology

Category:Structural proteins